Would you offer immunotherapy to a patient with stage II NSCLC with an EGFR exon 20 mutation?  

Data from Tsuji et al., PMID 38287788 and Naidoo et al., JCO 2022 suggest that patients with EGFRm NSCLC do not benefit from durvalumab after concurrent CRT. While the majority of patients studied had tumors driven by classic sensitizing mutations, atypicals were included in the series from Japan. B...

I believe the question is referring to adjuvant therapy following surgery and not after CRT. The SOC in fit stage 2 patients is surgery followed by adjuvant therapy. The choice for adjuvant therapy depends on the presence or absence of EGFR activating mutation and PDL-1 status.  Patients who...